$ANVS
Annovis Bio, Inc.
NYSE · Healthcare · Pharmaceutical Preparations · Malvern, PA
ANVS chart
What traders are saying about $ANVS
Latest postsAnnovis Bio, Inc. news
- Maxim Group Maintains Annovis Bio(ANVS.US) With Buy Rating, Maintains Target Price $8
Moomoo ·
- Annovis to Attend the CTAD 2026 with Three Presentations
Yahoo Finance ·
- AI research will predict which potential Alzheimer’s treatments reach the brain. It’s one of three Annovis presentations.
Stock Titan ·
- Parkinson's Disease Market Poised for Expansion During the Forecast Period (2026-2036) Amid JUVMO Approval and Emerging Therapeutic Innovations | DelveInsight
Yahoo Finance ·
- Annovis Announces Partnership with Weave Bio, AI Regulatory Platform, in Preparation of NDA for Buntanetap in Alzheimer’s Disease
Yahoo Finance ·
- Annovis Bio (ANVS) Loses 26.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Yahoo Finance ·
- Annovis Bio Targets March 2027 Alzheimer’s Readout, Prepares Rolling NDA
marketbeat.com ·
- Annovis to Host Corporate Update Webinar on September 2, 2026
Yahoo Finance ·
- Annovis Provides Corporate Updates and Second Quarter 2026 Financial Results
Yahoo Finance ·
- The Next Billion-Dollar Opportunity in Alzheimer's Disease Market: 6 Pipeline Therapies to Watch | DelveInsight
Yahoo Finance ·
- Annovis Bio Enrolls Over 850 Patients for Its Next Alzheimer's Disease Trial
Yahoo Finance ·
- Annovis Reaches Full Enrollment in Pivotal Phase 3 Trial of Buntanetap for Early Alzheimer’s Disease
Yahoo Finance ·
Annovis Bio, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net income | -$28.9M | -$24.6M | -$56.2M | -$25.3M |
| Diluted EPS | $-1.40 | $-2.31 | $-6.23 | $-3.10 |
| Total assets (year end) | $21.1M | $13.9M | $10.2M | $36.0M |
| Cash and equivalents (year end) | $19.5M | $10.6M | $5.8M | $28.4M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Annovis Bio, Inc.
- Ticker
- ANVS (NYSE)
- Industry
- Pharmaceutical Preparations
- Headquarters
- Malvern, PA
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 1477845
- Former names
- QR Pharma, Inc.
Frequently asked questions
What exchange is Annovis Bio, Inc. listed on?
Annovis Bio, Inc. trades on the NYSE under the ticker symbol ANVS.
What industry is Annovis Bio, Inc. in?
Annovis Bio, Inc. is classified by the SEC under "Pharmaceutical Preparations", part of the Healthcare sector on StockTweeting.
Where is Annovis Bio, Inc. headquartered?
Annovis Bio, Inc.'s business address on file with the SEC is in Malvern, PA.
When does Annovis Bio, Inc.'s fiscal year end?
Annovis Bio, Inc.'s fiscal year ends on December 31.
How much revenue did Annovis Bio, Inc. report?
Annovis Bio, Inc. reported $0 in revenue for calendar year 2025, according to its SEC filings.